Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Down 21.2% in March

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 31,600 shares, a drop of 21.2% from the February 28th total of 40,100 shares. Based on an average trading volume of 39,500 shares, the short-interest ratio is presently 0.8 days. Currently, 0.5% of the company’s stock are short sold.

Institutional Trading of Lisata Therapeutics

A hedge fund recently bought a new stake in Lisata Therapeutics stock. Citadel Advisors LLC purchased a new stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 23,273 shares of the company’s stock, valued at approximately $69,000. Citadel Advisors LLC owned 0.28% of Lisata Therapeutics as of its most recent filing with the SEC. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

Lisata Therapeutics Stock Performance

Shares of Lisata Therapeutics stock traded down $0.09 during trading on Wednesday, hitting $2.07. 16,131 shares of the company’s stock were exchanged, compared to its average volume of 20,816. The business has a 50-day simple moving average of $2.44 and a 200-day simple moving average of $2.81. The stock has a market capitalization of $17.84 million, a price-to-earnings ratio of -0.82 and a beta of 1.16. Lisata Therapeutics has a 52-week low of $2.05 and a 52-week high of $4.20.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.21. The firm had revenue of $1.00 million for the quarter. On average, equities analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Lisata Therapeutics in a research note on Wednesday, December 11th.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.